Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Menopause01:28

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.

Clinical genitourinary cancer·2020
Same author

Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study.

Clinical genitourinary cancer·2020
Same author

The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages.

Cancer causes & control : CCC·2020
Same author

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

European urology·2020
Same author

Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes.

Clinical genitourinary cancer·2020
Same author

Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2020
Same journal

When X Does Not Mark the Spot: Autosomal Dominant and Recessive Forms of Renal Hypophosphatemic Rickets and Osteomalacia.

Current osteoporosis reports·2026
Same journal

Beyond Fracture Probability: Communicating the Full Consequences of Fracture and Contextualization.

Current osteoporosis reports·2026
Same journal

Time-Lapse HR-pQCT: an in Vivo Imaging-Based Assessment of Bone Remodeling Dynamics.

Current osteoporosis reports·2026
Same journal

Cone Beam Computed Tomography of Bonejaws in Patients With Primary Osteoporosis: A Systematic Review.

Current osteoporosis reports·2026
Same journal

Testosterone and Bone Health in Men.

Current osteoporosis reports·2026
Same journal

Stimulant Medications and Bone Health.

Current osteoporosis reports·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

Androgen deprivation and bone.

Jean-Baptiste Lattouf1, Hicham Fadlallah, Fred Saad

  • 1Departments of Surgery and Urology, Centre Hospitalier de l'Université de Montréal, 1560 Sherbrooke East, Montreal, Quebec H2L 4M1, Canada. jean-baptiste.lattouf@umontreal.ca

Current Osteoporosis Reports
|December 17, 2010
PubMed
Summary
This summary is machine-generated.

Men with prostate cancer undergoing androgen deprivation therapy (ADT) face bone loss risks. Treatments like bisphosphonates and denosumab are available to manage bone health and prevent complications.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Related Experiment Videos

Last Updated: Jun 6, 2026

Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

Area of Science:

  • Oncology
  • Endocrinology
  • Bone Metabolism

Background:

  • Androgen deprivation therapy (ADT) for prostate cancer can lead to significant bone loss.
  • Maintaining bone health is crucial for patients undergoing long-term ADT.
  • Emerging therapies offer new strategies for managing treatment-related bone complications.

Purpose of the Study:

  • To review the importance of bone health in men with prostate cancer receiving ADT.
  • To provide an overview of current and emerging treatment modalities for bone loss.
  • To discuss guidelines for managing bone health in this patient population.

Main Methods:

  • Literature review of recent studies and clinical trials.
  • Analysis of available therapeutic options for bone loss prevention and treatment.
  • Examination of current clinical practice guidelines.

Main Results:

  • Vitamin D and calcium supplementation are foundational.
  • Bisphosphonates represent a potential treatment option.
  • Denosumab, a RANKL inhibitor, has demonstrated efficacy in preventing bone loss via randomized trials.

Conclusions:

  • Bone health is a critical concern for men on ADT.
  • A range of therapeutic interventions, including bisphosphonates and denosumab, are available.
  • Adherence to updated guidelines is essential for optimal patient management.